1	Combined pren	atal Lactobacillus reuteri and ω -3 supplementation			
2	synergistically modulates DNA methylation in neonatal T helper cells				
3 4 5	Johanna Huoman PhD ¹ , David Martínez-Enguita MSc ² , Elin Olsson MSc ² , Jan Ernerudh MD PhD ³ , Lennart Nilsson MD PhD ⁴ , Karel Duchén MD PhD ⁴ , Mika Gustafsson PhD ^{2*} and Maria C Jenmalm PhD ^{1*}				
6 7	¹ Division of Inflammation and Infection, Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden				
8	² Department of Physics, Chemistry and Biology, Linköping University, Linköping, Sweden				
9 10	³ Department of Clinical Immunology and Transfusion Medicine, Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden				
11 12	⁴ Allergy Center, Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden				
13					
14	*shared senior authorship				
15					
16	Corresponding author:	Johanna Huoman, PhD			
17		Division of Inflammation and Infection			
18		Department of Biomedical and Clinical Sciences			
19		Faculty of Medicine and Health Sciences			
20		Linköping University			
21		Lab 1, Building 420, entrance 68, level 12			
22		581 83 Linköping, Sweden			
23		E-mail: johanna.huoman@liu.se			
24		Phone: +46 76 069 63 38			
25					
26 27	Word count: 3491 words	s (Introduction, Results and Discussion. Including Methods, 5841			
28	Number of figures: 6 Fig	ures			
29	Number of tables: 2 Tables				
30	Material in electronic repository: 12 Supplementary Figures, 11 Supplementary Tables,				
31	mainly collected in Supplementary Appendix.				
32	NOTE: This preprint reports new reso	earch that has not been certified by peer review and should not be used to guide clinical practice.			

33 ABSTRACT

Background: Environmental exposures may alter DNA methylation patterns of T helper cells. 34 35 As T helper cells are instrumental for allergy development, changes in methylation patterns may constitute a mechanism of action for allergy preventive interventions. While epigenetic 36 effects of separate perinatal probiotic or ω -3 fatty acid supplementation have been studied 37 38 previously, the combined treatment has not been assessed. We aimed to investigate epigenome-wide DNA methylation patterns in cord blood samples from children in a 39 randomised double-blind placebo-controlled allergy prevention trial using pre- and postnatal 40 41 combined *Lactobacillus reuteri* and ω -3 fatty acid treatment. To this end, >866 000 CpG sites (MethylationEPIC 850K array) in cord blood CD4+ T cells were examined in samples from all 42 four study arms (double-treatment: n=18, single treatments: probiotics n=16, ω -3 n=15, and 43 double placebo: n=14). Statistical and bioinformatic analyses identified treatment-associated 44 differentially methylated CpGs and genes, which were used to identify treatment-induced 45 network modules. Pathway analyses inferred biological relevance, and comparisons were 46 made to an independent allergy data set. 47

Results: Comparing the active treatments to the double placebo group, most differentially 48 49 methylated CpGs and genes were hypermethylated, suggesting induction of transcriptional 50 inhibition. The double-treated group showed the largest number of differentially methylated CpGs, of which many were unique, suggesting synergy between interventions. Clusters within 51 the double-treated network module consisted of immune-related pathways, including T cell 52 53 receptor signalling, and antigen processing and presentation, with similar pathways revealed for the single-treatment modules. CpGs derived from differential methylation and network 54 55 module analyses were enriched in an independent allergy data set, particularly in the double-56 treatment group, proposing treatment-induced DNA methylation changes as relevant for allergy development. 57

Conclusion: Prenatal *L. reuteri* and/or ω -3 fatty acid treatment results in hypermethylation and affects immune- and allergy-related pathways in neonatal T helper cells, with potentially

60	synergistic effects between the interventions and relevance for allergic disease. Further
61	studies need to address these findings on a transcriptional level, and whether the results
62	associate to allergy development in the children. Understanding the role of DNA methylation
63	in regulating effects of perinatal probiotic and ω -3 interventions may provide essential
64	knowledge in the development of efficacious allergy preventive strategies.
65	
66	Key words (max 10): allergy prevention, combined intervention, cord blood, CD4+ T cells,
67	DNA methylation, Lactobacillus reuteri, MethylationEPIC 850K, ω -3 fatty acids, prenatal,
68	postnatal
69	
70	
71	
72	
73	
74	
75	
76	
77	
78	
79	
80	
81	
82	

83 INTRODUCTION

Present-day increases in allergy prevalence in urbanised societies may be caused by the extensive loss of diverse microbial exposures due to changed lifestyle habits, thereby affecting development of appropriate immune responses.^{1,2} This is particularly important throughout the perinatal period, when maternal exposures during pregnancy and breastfeeding lay the foundations of, and influence, immune development of the foetus and the newborn child.³⁻⁶ Hence, the maternal influence on the foetal immune system is significant, and the composition of both the maternal diet and her commensal microbiome is crucial in the process.^{7,8}

By supplementing pregnant women, with a high propensity of having an allergic child, during 91 92 pregnancy and lactation with ω -3 fatty acids and probiotics, it may be possible to modulate the foetal immune system towards tolerance.^{7,9,10} In Westernised societies the dietary fatty acid 93 intake favours ω -6 over ω -3 fatty acids ^{11,12}, thereby promoting production of pro-inflammatory 94 mediators, such as prostaglandins and leukotrienes ¹³, and possibly sustaining allergic 95 inflammation.¹⁰ However, by ω-3 supplementation this ratio may be altered and promote 96 downstream production of immunoregulatory mediators.¹⁰ ω-3 fatty acids may dampen allergic 97 inflammation by inhibiting effects of IL-4 and IL-13, as well as by preventing isotype switching 98 of B cells to IgE-antibodies.⁷ Indeed, prenatal ω -3 intervention attenuated IL-4 and IL-13 levels 99 in cord blood¹⁴, and decreased the risk of developing asthma in the offspring.¹⁵ Previously, we 100 have investigated the effects of pre- and postnatal ω -3 supplementation, demonstrating lower 101 102 prevalence of sensitisation and IgE-associated eczema throughout the first year of life¹⁶, and 103 a decreased risk of developing any IgE-associated disease up to two years of age¹⁷, in ω -3 compared to placebo-treated children. Several studies point at altered gut microbiomes in 104 children developing allergies¹⁸⁻²³, suggesting that increasing gut microbial diversity by e.g. 105 probiotic intervention may be helpful in allergy prevention.²⁴ Lactobacilli, a commonly used 106 107 family of probiotic bacteria, induce both innate and adaptive immunostimulatory responses, apart from improving barrier integrity and modulating gut microbiota composition.²⁵ We have 108 previously shown allergy preventive effects on IgE-associated eczema upon supplementation 109

with *Lactobacillus reuteri*.²⁶ Interestingly, children whose mothers had allergic symptoms revealed the greatest benefits of the *L. reuteri* treatment²⁶, whereas ω -3 treatment provided most benefit to children whose mothers did not have allergic symptoms.^{16,17} This suggests that combining the treatments could benefit allergy prone children regardless of maternal allergy status, and possible synergistic effects of the immunostimulating probiotics and the immunomodulatory ω -3 fatty acids could occur. However, this has thus far not been studied.

A suitable way to evaluate the effects of supplemental interventions would be to study 116 epigenetic modifications, since they regulate transcriptional accessibility of genomic regions in 117 response to environmental stimuli.²⁷ DNA methylation of CpG sites is considered the most 118 stable epigenetic modification, and is known to regulate the differentiation of T helper cells²⁸, 119 cells that are central in development of allergic disease.²⁷ Indeed, differential DNA methylation 120 patterns associate with development of sensitisation^{29,30}, asthma^{31,32} and food allergies^{33,34} in 121 children and adolescents. Epigenetic studies of prenatal fatty acid intervention have shown 122 effects on histone modifications³⁵, while others report conflicting results on DNA methylation 123 patterning.^{36,37} A study on epigenomic modulation of combined *L. rhamnosus* 124 GG/Bifidobacterium lactis in obesity³⁸ revealed general hypomethylation, in line with findings 125 from our previous study investigating *L. reuteri* in allergy prevention.³⁹ In newborns whose 126 mothers had been supplemented with L. reuteri throughout the last month of pregnancy, this 127 loss of methylation in CD4+ cord blood cells was prominent in genes related to immune 128 activation.³⁹ This indicates that treated children received a head-start in their immune 129 130 maturation, which hence may affect the development of allergic disease. However, in the context of combining probiotics and ω-3 fatty acids, neither clinical outcomes nor epigenetic 131 effects have yet been studied. 132

In the on-going PROOM-3 trial (PRObiotics and OMega-3, ClinicalTrials.gov-ID: NCT01542970), the allergy preventive effects of combined *L. reuteri* and ω -3 fatty acids supplementation, from mid-pregnancy throughout the first year of life of the child, are studied. In this paper, we examined epigenome-wide DNA methylation patterns in cord blood CD4+

cells from the PROOM-3 cohort. Our hypothesis was that the earlier initiated probiotic treatment will lead to more prominent effects on DNA hypomethylation in immune-related genes compared to the previous study.³⁹ Likewise, we hypothesised that ω -3 fatty acid supplementation will lead to hypomethylation of immune-related sites, and possibly work synergistically with the probiotic intervention to cause the greatest differential methylation in immunological pathways. Our findings indicate that the epigenome is modulated by the prenatal treatment with probiotics and ω -3 fatty acids, which may have implications for developing and improving future allergy prevention strategies.

- ____

160 **RESULTS**

Differential DNA methylation analyses reveal mainly hypermethylated CpGs and genes upon supplementation with *L. reuteri* and/or ω-3 fatty acids

163 Comparisons of demographic variables revealed no differences between the treatment groups, 164 except for a higher proportion of females in the ω -3 single active treatment (P ω) group (Table 165 1). This lead us to exclude the sex chromosomes from further analyses, as retaining them might affect downstream results. Thereafter, we pursued multidimensional scaling (MDS) 166 167 analyses to investigate inherent differences between the three active treatment groups, the 168 double L. reuteri and ω -3-treated group (L ω), the L. reuteri single-treated group (LP) and the 169 ω -3 single-treated group (P ω), compared to the double placebo group (PP). These analyses revealed distinct differences between the treated and untreated groups (Figure 1A-C), 170 indicating treatment-associated changes at the epigenome level. We then proceeded to 171 172 analyse differential DNA methylation, using an FDR-adjusted p-value threshold of <0.1 along with a mean methylation difference (MMD) of > 5% to define differentially methylated CpGs 173 (DMCs). The double-treated L ω group demonstrated the highest number of DMCs compared 174 with the single active treatment groups (L ω : 1659, LP: 1246 and P ω : 984 CpG sites, 175 respectively. Table 2). A majority of the DMCs were hypermethylated (58-70%, Table 2, Figure 176 1 D-E, Table S1) in all three comparisons, suggesting that prenatal treatment with probiotics 177 and/or ω-3 fatty acids foremostly leads to transcriptional inhibition. To investigate the biological 178 impact of these findings, the DMCs were mapped to their corresponding differentially 179 180 methylated genes (DMGs), which thereafter were utilised for pathway enrichment analyses. The double-treated Lw group contained 794 genes compared to 620 and 494 genes in the 181 single-treated LP and Pw groups, respectively (Figure 2, Table S2), and 72 genes were shared 182 for all three comparisons (Figure 2, Table S3). Pathway enrichment analyses of the DMGs in 183 184 the respective comparisons revealed 87 pathways for the L ω group, including immune-related 185 pathways such as PI3K-Akt and MAPK signalling,


- 186 **Table 1.** Demographic characteristics of children with available cord blood samples from the PROOM-
- 187 3 study.

Intervention	1			22	
group	Lω	LP	Ρω	PP	
Croup description	L. reuteri +	L. reuteri +	Placebo +	Placebo +	
Group description	ω-3 PUFA	Placebo	ω-3 PUFA	Placebo	
and size	n=18	n=16	n=15	n=14	
Female	6/18 (33%)	7/16 (44%)	12/15 (80%)*	3/14 (21%)	
Birth week	39.5 (39.0-41.0)	40.0 (38.8-40.2)	40.0 (40.0-41.0)	40.0 (39.0-41.0)	
Treatment duration	19.0 (19.0-21.2)	19.5 (19.0-20.0)	20.0 (19.5-21.0)	20.0 (19.0-20.8)	
Maternal age (birth)	31.0 (29.0-32.8)	32.0 (30.0-33.2)	32.0 (29.0-33.0)	30.0 (28.2-32.5)	
Caesarean delivery	3/17 (18%)	0/16 (0%)	1/15 (7%)	1/14 (7%)	
Birth weight (kg)	3.8 (3.6-3.9)	3.5 (3.3-3.9)	3.9 (3.7-4.1)	3.8 (3.6-4.1)	
Birth height (cm)	51.0 (50.0-52.0)	51.5 (49.8-52.2)	51.0 (50.5-52.5)	51.0 (50.0-52.0)	
Maternal atopy	14/18 (78%)	11/16 (69%)	7/15 (47%)	8/14 (57%)	
Paternal atopy	9/18 (50%)	9/16 (56%)	9/15 (60%)	11/14 (79%)	
Siblings	1.0 (0.0-1.0)	1.0 (0.0-1.2)	1.0 (0.0-1.5)	0.0 (0.0-1.0)	
People in home	4.0 (3.0-4.0)	4.0 (3.0-5.0)	3.0 (3.0-4.0)	3.5 (3.0-4.0)	
Smoking in home	0/18 (0%)	0/16 (0%)	0/12 (0%)	1/14 (7%)	
Breastfeeding	15/18 (83%)	12/16 (75%)	9/12 (75%)	12/14 (86%)	
(at 3 months)					
Antibiotics (during	1/15 (7%)	1/14 (7%)	0/10 (0%)	0/11 (0%)	
first 3 months)	1/15 (7 /6)				
Pets in home 4/18 (22%)		5/16 (31%)	3/11 (27%)	1/13 (8%)	
(at 3 months)	4/10 (22 /0)	0,10 (01,0)	0/11 (27 /0)	1/10 (070)	
Naïve	95.6 (94.6-97.4)	96.6 (95.7-97.1)	95.7 (95.3-97.3)	95.9 (94.5-96.9)	
CD4+CD45RA+					
cells (%)					
Memory		3.4 (2.9-4.3)	4.3 (2.7-4.7)	4.1 (3.1-5.5)	
CD4+CD45RA-	4.4 (2.6-5.4)				
cells (%)					

188

Demographic variable information was retrieved from parentally reported questionnaire data at the three month follow-up. Continuous variables are expressed as medians with interquartile ranges and were analysed using the Shapiro-Wilk's test of normality followed by Levene's test of equal variances and the Kruskal-Wallis H test. For the categorical variables, the Pearson χ^2 test was performed and the data is presented as n/N (%). *denotes significantly more females than males in the P ω group, p=0.01. L – *Lactobacillus reuteri*, $\omega - \omega$ -3 fatty acids, P – placebo.

194 **Figure 1**.



195 Figure 1. Graphical representations of multidimensional scaling (MDS) analyses are shown in panels A-C for the double active (L ω) and single active treatment groups (LP, P ω), respectively, in comparison 196 197 to the double placebo group (PP). Red dots represent the active treatment group, blue dots the placebo 198 group. In panels D-E, volcano plots illustrate the distribution of DMCs when comparing each of the active 199 treatment groups to the double placebo group (PP). DMCs are defined as having an MMD of > 5% along 200 with an FDR-corrected p-value of < 0.1, and are depicted as red dots. DMC – differentially methylated 201 CpG, MDS - multidimensional scaling, MMD - mean methylation difference, L - Lactobacillus reuteri, 202 $\omega - \omega$ -3 fatty acids, P – placebo.

Phospholipase D signalling and T cell receptor signalling (Table S4). The LP group revealed
20 pathways, amongst others the Rap 1, Phospholipase D signalling and Th17 differentiation
pathways (Table S5), whereas the Pω group did not reveal any pathways at all.


Table 2. Results from the differential methylation analyses, comparing the active treatments *vs.* thedouble placebo group.

Intervention group	Lω vs. PP	LP vs. PP	Pω vs. PP
DMCs	1 659	1246	984
Hypomethylated CpGs	576 (35%)	380 (30%)	415 (42%)
Hypermethylated CpGs	1083 (65%)	866 (70%)	569 (58%)
DMGs	794	620	494
Hypomethylated genes	247 (31%)	204 (33%)	184 (37%)
Hypermethylated genes	524 (66%)	405 (65%)	295 (60%)
Mixed methylation genes	23 (3%)	11 (2%)	15 (3%)

209

210 Proportions of hypo- and hypermethylated CpGs and genes, from the differential DNA methylation analyses 211 comparing the active treatment groups vs. the double placebo group, are presented as n (% of total). DMCs 212 – differentially methylated CpGs, DMGs – differentially methylated genes, L – *Lactobacillus reuteri*, 213 $\omega - \omega$ -3 fatty acids, P – placebo.

214 Figure 2.



intersect. sizes


Figure 2. A graphic representation of overlapping DMGs between the different comparisons. The sets represent the different comparisons, and the intersectional sizes show the number of overlapping genes between the comparisons. Dark blue represents the double-treated group, light blue the *L. reuteri* singletreated group and coral blue the ω -3 single-treated group. L – *Lactobacillus reuteri*, $\omega - \omega$ -3 fatty acids, P – placebo.

227 Network analyses show immune-related pathways being affected by the interventions

228 As a means to further elaborate on the wider biological context in which the supplementation-229 induced DMGs act, the DMGs were mapped onto a protein-protein interaction map (STRING-230 db) to study putative interactions in a network context. The most interconnected modules were derived from DMGs identified by four module discovery methods from the MODifieR⁴⁰ package. 231 232 This approach narrowed down the number of supplementation-induced DMGs to 170, 100 and 87 genes for the Lw, LP and Pw comparisons, respectively (Tables S6-S8). High-confidence 233 234 interactions from the respective modules are displayed in Figure 3 and Figures S2-3. Of the 170 genes identified in the double-treated L ω module, six genes were considered highly 235 236 connected (exhibiting 10 or more connections to other module genes), and could be 237 considered important hubs within the network: FYN, GNB5, SNAP23, LAMC1, IL6 and RAF1 (Figure 3). All genes but IL6 were hypermethylated. Inspecting the network module for 238 239 biologically relevant clusters, pathway enrichment analyses of those clusters revealed that supplementation with both L. reuteri and ω -3 affects pathways such as T cell receptor 240 signalling, antigen processing and presentation as well as TGF- β signalling (Figure 3, Figure 241 242 S3), clusters that were also observed in corresponding analyses of the single-treated groups 243 (Figures S1-2, S4-5).

To further evaluate common and unique features of the obtained supplementation modules. 244 comparisons were made between the three treatment groups. While 10 genes were shared 245 246 between all three comparisons, 24, 14 and 10 genes overlapped when comparing the L ω group 247 to the *L. reuteri* single-treated (LP) group, the L ω to the ω -3 single-treated (P ω) group and the single-treated groups (LP vs. Pw) to each other, respectively (Figure 4A, Table S9). Genes 248 common to all treatment groups related to cellular adhesion and extracellular matrix-receptor 249 interaction pathways, whereas the comparisons between the single-treated groups revealed 250 251 no significant pathways. Compared to the Lω double-treated group, overlaps to the single-252 active Pw group related to T cell receptor signalling and other related signal transduction pathways, while overlaps to the LP group included Ca2+ signalling and O-glycan biosynthesis 253






255 Figure 3. Visualisation of the consensus module created with the DMGs from the differential methylation 256 comparison between the double-treated *L.reuteri*/ ω -3 (L ω) and the double placebo (PP) group. Nodes 257 represent genes and connecting lines represent protein-protein interactions (STRING combined score 258 > 0.7) within the network. Red nodes illustrate hypermethylated genes, blue nodes indicate 259 hypomethylated genes and both colours denote mixed methylation patterns. Black lines enclose 260 biologically relevant clusters identified by bioinformatic pathway enrichment analyses. Nodes marked 261 with * are also present in an independent allergy data set (described later in the paper). DMGs differentially methylated genes, L – Lactobacillus reuteri, $\omega - \omega$ -3 fatty acids, P – placebo. 262


(Figure 4A), pathways which are relevant for proper T cell function. The largest number of 263 unique genes were revealed for the double active L ω treatment group (122 genes), which were 264

mainly biologically related to T cell receptor signalling and related signal transduction pathways, TNF and NF κ B signalling as well as asthma (Figure 4B). The single-treated groups showed similar numbers of unique genes (LP: 56 genes, P ω : 53 genes), which related to Th1/2/17 helper cell differentiation and asthma amongst other pathways for the LP group, while yet again no relevant pathways were discovered for the P ω treatment group. Hence, combined probiotic and ω -3 supplementation seems to have synergistic effects at the network level compared to the single treatments.

272 Further evaluation of the direction of methylation in the shared genes revealed that treatment with either *L. reuteri* or ω -3 fatty acids led to consistent methylation patterns in most of the 273 genes when compared to the double-treated L ω group (Figure 5A-B, Table S9). This pattern 274 275 was even more distinct comparing the single active treatment groups, where only one gene revealed different methylation patterns between the groups (Figure 5C). In the comparison 276 between all three treatment groups, however, the patterning of approximately half the genes 277 were similar, whereas the single active groups exhibited different and still distinct shared DNA 278 methylation patterns with the L ω group (Figure 5D). 279


280 Figure 4.





294 Figure 4. Venn diagrams illustrating the degree of overlap and uniqueness for the obtained genes from 295 the three network modules for the double active treatment (Lw vs. PP) and the single active treatment 296 (LP vs. PP, Pw vs. PP) comparisons. In panel A, the number of common genes from the overlap are 297 displayed for each comparison is shown, with corresponding gene names denoted in italics, and 298 selection of related pathways in bold. No relevant pathways were revealed for the shared genes of the 299 LP vs. PP and Pw vs. PP comparisons. In panel B. the number of genes that are unique for each 300 comparison are displayed along with a selection of corresponding related pathways. No pathways of 301 relevance were revealed for the unique genes from the Pω vs. PP comparison. L – Lactobacillus reuteri, $\omega - \omega$ -3 fatty acids, P – placebo. 302

Figure 5. 303



304 Figure 5. River plots illustrating the methylation status for overlapping genes being shared between the 305 double-treated Lw group and A. the single-treated probiotic (LP vs. PP), and B. w-3 treated (Pw vs. PP) 306 group. Panel C. illustrates comparisons between the single treated groups (LP and P ω vs. PP) and D. 307 shows the comparison between all treatment groups. Genes are represented as flows of size 308 proportional to number of genes within their methylation status in a particular set, and differences 309 between sets are shown as connections between flows. The respective gene names are denoted next to each flow. Red represents hypermethylation, blue hypomethylation and green a mixed methylation 310 311 pattern. The number of genes in the respective flows are denoted in the graph. L - Lactobacillus reuteri, 312 $\omega - \omega$ -3 fatty acids, P – placebo.

Differentially methylated CpGs in the active treatment groups were enriched in an 313 independent allergic disease data set 314


As no information is as yet available on allergy development for the children included in this 315 study, we pursued enrichment analyses on DMCs extracted from the differential DNA 316

methylation analyses for all three comparisons, and compared them to DMCs of a publicly 317 available allergy data set, studying DNA methylation patterns in CD4+ T cells of adults with 318 seasonal allergic rhinitis (8 patients vs. 8 controls). Indeed, for all three comparisons, a 319 320 substantial number of DMCs were significantly enriched within the allergy data set (L ω : 91, p=4.7e⁻²⁸, LP: 47, p=2.6e⁻¹¹ and P ω : 56 CpGs, p=1.9e⁻¹⁷, Figure 6A). Investigating involved 321 pathways of the genes from these DM.Ce-s, few or no pathways emerged (results not shown). 322 Three CpG sites overlapped between the three groups (in the genes MYOF, C6orf123 and 323 324 PTPRN2), while additionally 8 and 11 CpGs were common comparing the the double-treated L ω group to the single-treated LP and P ω groups, respectively, and 4 CpGs were overlapping 325 326 between the single-treated groups (Table S10).

327 As some results from the network analyses indicated involvement of network genes in allergyrelated pathways, we additionally pursued comparisons of our DMCs from the consensus 328 329 modules for all three comparisons to the above mentioned allergy data set. Enrichment analyses revealed that there was a significant overlap between our DMCs identified by the 330 double-treated L ω network module and allergic disease (9 genes, p=0.00021, Figure 6B), while 331 332 no significant enrichments were revealed for the single-treated groups. Examining these nine genes within the L ω module in more detail, four were hypomethylated (*TNF*, FAS, TRAT1 and 333 HIVEP3), while five were hypermethylated (SLC44A2, MFGE8, EPHA4, BCL7A and 334 335 RAB11FIP1), and seven of these genes were present within the connected components of the 336 network (all but HIVEP3 and RAB11FIP1, Figure 3, genes marked with asterisks). Six out of 337 seven genes were furthermore located to the central parts of the network, mainly involved in T cell receptor signalling and antigen processing and presentation. Comparing the direction of 338 methylation to the independent allergy data set, four genes exhibited the opposite direction of 339 patterning (HIVEP3, TRAT1, BCL7A and SLC442A), while the DNA methylation patterning of 340 341 the remaining genes were identical between the groups (Figure S6).

342

344 Figure 6.



345

346 Figure 6. Enrichment analyses relating DMCs from A. differential DNA methylation analyses and B. 347 network analyses for all three comparisons, to DMCs from a study investigating DNA methylation 348 patterns in adults with seasonal allergic rhinitis. Panel A. shows treatment DMC overlaps with allergy DMCs. Panel B. shows consensus module gene associated DMC overlaps with allergy DMCs. The 349 350 number of overlapping DMCs is shown at the bottom of the bars (n). A one-sided Fisher's exact test 351 was used for the enrichment analyses. Computed P-values represent the enrichment significance, while 352 the fold enrichment illustrates how over-represented the overlap is, compared to what would be 353 expected by chance for the given background.

- 354
- 355
- 356
- - -
- 357
- 358
- 359
- 360
- 361

362 **DISCUSSION**

The role of perinatal combined allergy prevention interventions on epigenetic patterning in T helper cells has hitherto been unknown. In this paper, we set out to assess the epigenomewide effects on cord blood CD4+ cells of combined maternal probiotic and ω -3 intervention during the latter half of pregnancy. Indeed, we show that prenatal supplementation affects the epigenome of T cells from cord blood in the neonates substantially, and differently so depending on the treatment combination.

369 The main finding of this study was that the largest treatment-induced effect on the epigenome 370 was revealed in the L ω double active treatment group, and that regardless of treatment 371 hypermethylation was the main outcome. The network analyses revealed the same pattern in the created intervention modules, and the genes shared between the comparisons as well as 372 the performed network analyses revealed common biological pathways. The L ω module made 373 374 up the highest number of genes while fewer, but still significant, numbers were revealed in the single-treated LP and Pw modules. This indicates that there might be some synergistic effects 375 of the double treatment. Although the number of shared genes from the networks were limited 376 and the methylation patterns of the genes were only partly similar, this further suggests that 377 the combined treatment may modulate the epigenetic response differently from the single 378 treatment groups. Probiotics may affect DNA methylation either by the production of 379 metabolites downstream of short chain fatty acids, which are indispensable co-factors for 380 proper functioning of enzymes such as DNA methyltransferases, or directly by modifying the 381 actions of the same enzymes.⁴¹ Similarly, ω-3 fatty acid intervention may alter DNA 382 methyltransferase activity⁴² and regulation of transcription factor activity.⁴³ However, how the 383 combination of the two treatments act on a molecular level still needs further elaboration. 384 Examining the genes that were unique to the respective comparisons, the L ω and LP groups 385 386 featured large numbers of immune-related pathways, yet again involving signal transduction 387 pathways important for T cell signalling, but also T helper cell differentiation and asthma. This is particularly interesting, and future studies on these children will have to settle whether 388

induced DNA methylation differences are associated with the development of allergic disease.
 Altogether, our findings propose that the interventions modulate the epigenome, and more
 specifically so in pathways that are of general importance for proper T cell development and
 function.

To further understand the impact of the prenatal intervention on the epigenome, genes that 393 were highly connected within the module network were scrutinised in detail. In the double-394 395 treated L ω group, six genes had more than 10 connections to other genes within the network. 396 One of the genes was FYN, a non-receptor tyrosine-protein kinase involved in the downstream signal transduction pathway of the T cell receptor, regulating amongst other things T cell 397 activation and differentiation.⁴⁴ In this study, FYN was hypermethylated, suggesting that the 398 gene would be transcriptionally silenced by treatment and thereby also downregulating 399 putative protein functions. Another gene of interest was the hypomethylated inflammatory 400 cytokine gene IL6. IL-6 is heavily involved in the development and maintenance of 401 inflammation, by inducing both innate and adaptive inflammatory immune responses.⁴⁵ In 402 modulation of the latter, IL-6 regulates both proliferation and cytokine responses of CD4+ cells 403 404 by inducing JAK/STAT, MAPK and PI3K-Akt signalling pathways, and downstream effects of this activation have been implicated in development of asthma. On an epigenomic level, 405 hypomethylation of IL-6 has been shown in children with peanut allergy⁴⁶, and it has also been 406 associated to worse lung function in asthmatic children.⁴⁷ Furthermore, in the first 6-12 months 407 of life, the IL6R gene was hypomethylated in a pre-and postnatal probiotic intervention study 408 investigating development of obesity in children.³⁸ As we are still collecting information about 409 410 development of allergic disease such as asthma in the present PROOM-3 study, the long term implications of this finding are unknown. It is possible, however, that the intervention enables 411 transcriptional accessibility of this gene, and hence equips the child with early inflammatory 412 413 capacity. This notions is in line with the observed overlap of DMCs from the L ω consensus module with the publicly available allergy data set. Three hypomethylated genes from the T 414 cell receptor signalling cluster were of particular interest: TNF, FAS and TRAT1. The T cell 415

receptor-associated transmembrane adaptor protein TRAT1 is known to stabilise the T cell 416 receptor/CD3 complex, and may thereby modulate downstream signal transduction and 417 promote T cell function.^{48,49} TRAT1 was hypomethylated in the L ω group, whereas it was 418 419 hypermethylated in the independent allergy data set, indicating that the combined intervention may enable proper T cell signalling propagation into the cell. While the cytokine tumor necrosis 420 factor (TNF) may not only promote inflammatory responses and induce proliferation of both 421 422 naïve and memory T cells, it may also drive apoptosis of effector T cells.⁵⁰ Similarly, the TNF-423 related FAS receptor may also induce apoptosis of cells by binding to FASL, leading to recruitment of caspase-8 and -10 and subsequent commencement of programmed cell 424 death.⁵¹ This process is of crucial importance in the establishment of peripheral tolerance, and 425 426 as TNF and FAS were hypomethylated in the L ω comparison, this suggests that antiinflammatory effects of TNF and FAS could be promoted by the supplementation of probiotics 427 428 and ω -3 prenatally. However, further studies on transcriptional and protein levels of these 429 mediators, along with functional studies in relation to allergy development should shed light on the relevance of these findings upon prenatal interventions. 430

431 One quite surprising finding of this study was that, in contrast to our hypothesis and results from our previous epigenome-wide study on the effects of perinatal L. reuteri treatment on cord 432 blood CD4+ cells³⁹, a larger proportion of the CpG sites were hypermethylated when 433 comparing either of the intervention groups to the double placebo group. This finding could 434 435 have several explanations. First of all, unlike our previous studies investigating possible allergy preventive effects of perinatal probiotic intervention³⁹ or ω -3 intervention^{16,17} the combined 436 437 intervention was initiated already at gestational (GW) 20 in the PROOM-3 study, compared to GW 25 for ω -3 fatty acid¹⁶ and GW 36 for *L. reuteri*⁵² supplementation in the previous study. 438 Additionally, the maternal dosage of the L. reuteri strain was also higher by an order of 439 magnitude in this study (10^9 colony forming units (CFU), compared to 10^8 CFU previously⁵²), 440 possibly allowing for potentiated effects of the probiotic intervention. Furthermore, we here 441 utilised Illumina's Infinium MethylationEPIC 850K array, surveying more than 866 000 sites all 442

over the genome. Despite including more than 90% of the investigated sites from the previous 443 Illumina 450K platform⁵³, almost twice the amount of DNA methylation probes were 444 445 investigated. This could possibly explain why the present findings differ from the previous study 446 where the Illumina 450K platform was used. Also, as only autosomal chromosomes were retained the present analyses, this may have affected the outcomes in relation to our previous 447 study³⁹, where all chromosomes were included in the analyses. Altogether, these modifications 448 to the study, experimental and statistical protocol could possibly explain the apparent reversed 449 450 observations in terms of major hypermethylation upon intervention with L. reuteri and/or ω -3 fatty acids in this study, in contrast to hypomethylation upon L. reuteri intervention previously.³⁹ 451

Advantages of the present study include the performance of the DNA methylation analyses in 452 453 purified CD4+ T cells, cells which are instrumental for development of specific long-term immune responses in general, but also for the development of allergic diseases in particular.² 454 Also, despite our relatively small sample numbers, we are able to evaluate all four intervention 455 groups in this study, enabling us to shed light on treatment-specific effects on the methylome. 456 The performance of network analyses provides another benefit of this study, where the 457 458 analyses have generated putative candidate genes to study further in an allergy development and prevention context. As the study is still on-going, we were not able to perform any 459 comparisons of the interventions and their respective DNA methylation patterns on outcomes 460 of allergy development. However, we made up for this drawback by comparing our findings to 461 462 an independent allergy study, where we indeed could show enrichment of our DMCs. Another 463 limitation in our analyses include the lack of validation at the mRNA or protein expression level.

In conclusion, we demonstrate that the combined prenatal treatment with *L. reuteri* and/or ω-3 fatty acids results in general differential hypermethylation in neonatal CD4+ T cells, which affects both T cell-specific and immune-related pathways. This was corroborated by network analyses that condensed the findings to differentially methylated genes in linked pathways, which also showed relevance in an independent cohort of allergic disease. Future follow-ups on allergic disease and studies on transcriptional activity will confirm the long-term relevance

- of the presented findings, which may have an impact on future development of allergy prevention regimens.

491 METHODS

492 Study participants

In this study, cord blood samples collected at the time of birth were included for 63 children 493 494 from the on-going randomised double blind placebo-controlled trial PROOM-3 495 (ClinicalTrials.gov-ID: NCT01542970), in which the allergy preventive effects of combined preand postnatal Lactobacillus reuteri and ω -3 fatty acid supplementation are investigated. The 496 study is four-armed comprising the following groups; double active treatment (Lw, L. reuteri 497 and ω -3 fatty acids), single active treatments (placebo for either treatment, active treatment for 498 499 either L. reuteri (LP) or ω -3 (P ω)) and double placebo treatment (PP). In the present study, the following numbers of samples were available per group: $L\omega = 18$, LP = 16, $P\omega = 15$, PP = 14. 500 501 The mothers are supplemented with the probiotic intervention or the corresponding placebo 502 supplement from GW 20 until delivery, whereas the children receive the same treatment 503 throughout the first year of life. The active probiotic substance consists of *L. reuteri* (BioGaia[®], Stockholm, Sweden) suspended in sun flower and palm kernel oil, which is given as droplets 504 twice daily to the mothers (10⁹ CFU) and once daily to the children (10⁸ CFU). Placebo 505 treatment for the probiotic intervention consists of the same oil mixture as above without 506 probiotics. The ω -3 fatty acid intervention or corresponding placebo supplement are given from 507 508 GW 20 throughout lactation to the mothers. Twice daily, the mothers ingest either three capsules of Pikasol[®] (Orkla Health, Lund, Sweden, 1 g capsules containing 640 mg ω-3 PUFA, 509 35% EPA, 25% DHA) or the placebo supplement olive oil. The children are followed-up at 510 511 several occasions using questionnaires and by performance of clinical examinations. As the study still is ongoing, only parent reported questionnaire data from the 3-month follow-up were 512 included for the purpose of this study. Parents or legal guardians provided informed consent 513 on behalf of the children prior to inclusion in the study. Ethical permission for this study has 514 515 been granted by the Regional Ethics Committee for Human Research in Linköping (Dnr 516 2011/45-31).

517

518 Cord blood mononuclear cell and CD4+ magnetic bead isolation

The isolation of cord blood mononuclear cells (CBMCs) from cord blood and the following magnetic bead isolation of CD4+ T cells from the CBMCs have been described in detail elsewhere.³⁹

522

523 Flow cytometry measurements of naïve and memory T cell proportions

524 In order to determine the proportion of naïve and memory cells from the isolated CD4+ cells 0.2 x 10⁶ cells were stained for flow cytometry. Firstly, in order to determine the amount of live 525 and dead cells in each sample Aqua LIVE/DEAD[™] Fixable Dead Cell Stain (Invitrogen, 526 527 Eugene, OR, USA) reconstituted reagent (according to manufacturer's protocol) was diluted 1:500 in PBS (Medicago AB, Uppsala, Sweden) + 0.1% FCS (Sigma-Aldrich, Ayrshire, United 528 Kingdom) and added to the samples for 15 minutes at RT. Thereafter, the cells were further 529 stained with CD4 PerCP (SK3) and CD45RA FITC (L48), with a complementary isotype tube 530 531 including CD4 PerCP and Mouse v1 FITC (X40) (all antibodies: Becton-Dickinson, San José, 532 CA, USA) for 15 min at 4°C. After washing the cells, they were resuspended as described previously³⁹ and 10 000 events were collected on a FACS Canto II instrument using the FACS 533 Diva software (version 8.0.1). The flow cytometry data were analysed using Kaluza (version 534 535 2.1, Beckman Coulter, Indianapolis, IN, USA), and the utilised gating strategy is presented in 536 Figure S7.

537 **DNA extraction**

From the remaining CD4+ cells, DNA was extracted using Allprep RNA/DNA Mini Kit (Qiagen, Austin, TX, USA) according to the manufacturer's instructions. DNA concentrations were measured using Qubit dsDNA BR Assay Kit (Thermo Fischer Scientific, Waltham, MA, USA) according to the manufacturer's instructions on a Qubit 3.0 fluorometer device (Thermo Fischer Scientific, Waltham, MA, USA). DNA samples were sent to the SNP&SEQ-technology platform at SciLifeLab (Uppsala University, Uppsala, Sweden) for the performance of Illumina's Infinium

Human MethylationEPIC 850K bead chip array preceded by bisulphite conversion on site. The
amount of DNA for each sample ranged from 1000-1800 ng.

546

547 Statistics

As the study is still on-going, the study has not yet been unblinded. An independent statistician has provided the code key only to collaborators that have not been involved in sample collection or laboratory experiments, as not to bias the investigators in interpretation of the data.

552 Descriptive analyses of demographic variables were performed. Continuous variables were 553 tested for normality using the Shapiro-Wilk test of normality followed by Levene's test of equal 554 variances. Thereafter the Kruskal-Wallis H test was performed to study differences in 555 proportions between the groups. For the categorical variables, the Pearson χ^2 test was 556 performed.

557

558 **DNA methylation analyses**

The generated raw data from the Illumina 850K MethylationEPIC arrays were processed in GenomeStudio (version 2011.1, Illumina Inc.) by the SNP&SEQ-technology platform, to render IDAT-files manageable for downstream analyses in the R programming environment (version 3.6.3).

563

564 **Pre-processing and quality control**

The raw DNA methylation data were pre-processed using the ChAMP⁵⁴ package (version 2.16.1) for the R programming environment. Probes with detection p-values above 0.01 and multi-hit probes were filtered out, as were non-CpG probes and probes related to SNPs and NA-probes. Furthermore, as we found significantly more females in the single active ω -3

treated ($P\omega$) group, and as X-inactivation in females skews the beta value distribution (Figure 569 570 S8), probes located on the X and Y chromosomes were omitted from the data. After the filtration step, 738 451 CpGs of the initial 865 918 investigated CpGs in the Illumina 571 572 MethylationEPIC 850K array remained. Thereafter, beta values were calculated for all probes, representing the mean methylation of each CpG site, and to adjust for the inherently different 573 designs of the Illumina DNA methylation arrays, normalisation of the beta values was 574 conducted using the beta mixture quantile (BMIQ) method.⁵⁵ In order to identify the most 575 576 significant components of variation in the data, and correct for unwanted variation if found, singular value decomposition (SVD) analyses were performed on the filtered and normalised 577 data, using the ChAMP package. Based on results from these analyses, corrections were 578 579 made in the data for the technical factors array and slide (Figure S9). The quality of the data 580 was examined prior to and after the normalisation step (Figure S10). To ascertain possible 581 differences in cellular content of the included samples, several methods were used to validate 582 the findings. Maternal contamination of the cord blood samples was examined on the unfiltered data using the method proposed by Morin et al.⁵⁶ By surveying threshold DNA methylation 583 584 levels of 10 specified CpG sites, samples with values above the threshold values at five or 585 more sites indicate contamination and should be excluded. Six samples had a beta value above the threshold value at one CpG site and one sample had beta values above the 586 threshold values at two CpG sites (data not shown), indicating no maternal contamination and 587 588 hence all 63 samples were retained in further downstream analyses. The cell type composition 589 of the samples was evaluated on filtered and normalised samples using the Houseman method.⁵⁷ The majority of cells were CD4+ cells with median proportions in the intervention 590 591 groups between 94-96% (Table S11), indicating high sample purity and successful isolation of 592 CD4+ T cells. Multidimensional scaling (MDS) analyses were performed on the filtered, 593 normalised and batch corrected data to study inherent differences in the data, using the R package minfi (version 1.32.0). Results of the SVD analyses using the ChAMP package 594 showed that, apart from the sample array and slide, sex was a major source of unwanted 595 596 variation in the normalised data. Therefore, sex was added as a co-variate in the batch

597 correction step for the data used in the MDS analyses, using the ComBat function⁵⁸ from the 598 sva package⁵⁹ (version 3.34.0), implemented in ChAMP. Following the statistical analyses, the 599 MDS results were graphically represented by assigning the samples to their respective 600 intervention group belonging.

601

602 Differential DNA methylation analysis

Using the limma package (version 3.42.2), differentially methylated probes were identified by 603 fitting the DNA methylation data to a linear model. As the proportion of males and females in 604 605 the samples of at least one of the groups was skewed, sex was included as a co-variate in the model, as was the proportion of memory CD4+ T cells in order to account for possible 606 differences in T cell subtypes. Moderated t-statistics, log2 Fold Change (logFC) and p-values 607 were computed for each investigated probe. The logFC values represents the average beta 608 methylation difference (from hereon referred to as mean methylation difference, MMD) 609 between the respective active intervention groups in relation to the double placebo (PP) group. 610 611 P-values were adjusted for multiple testing using the Benjamini-Hochberg procedure for False 612 Discovery Rate (FDR) correction. Differentially methylated CpGs (DMCs) were defined as probes having an FDR-adjusted p-value of less than 0.1 along with an MMD of > 5%. Volcano 613 614 plots were constructed to graphically illustrate the distribution of the DMCs using the base R environment. Identification of genes of interest was conducted by mapping the DMCs to the 615 genome, resulting in differentially methylated genes (DMG). The DMGs were defined as genes 616 617 containing at least one DMC, where hypomethylation was defined as all DMCs being hypomethylated and vice versa for the hypermethylated DMGs. Genes containing both hypo-618 and hypermethylated sites were considered having a mixed methylation pattern. A total of three 619 differential methylation comparisons were made between each of the treatment groups 620 compared to the double placebo group. The quality of these comparisons was ascertained 621 using several approaches. First of all, the genomic inflation rate was investigated for the t-622 statistics of each of the three comparisons described above, as the large number of statistical 623

comparisons made within each analysis may render a considerable number of false positive 624 625 results. The genomic inflation and pertaining bias were estimated and QQ-plots plotting the differential DNA methylation data against a normal distribution were constructed using the R 626 627 package BACON⁶⁰(version 1.14.0). The estimated inflation values for each of the three comparisons was very close to one in all cases, indicating that there was no substantial 628 genomic inflation in the comparisons (Figure S11), and hence no correction was needed. 629 Pathway enrichment analyses were performed on the identified DMCs from the differential 630 631 DNA methylation analyses, using the clusterProfiler package (version 3.14.3) and the KEGG PATHWAY database (release 94 2020/04). An adjusted p-value cut-off of 0.1 was chosen to 632 633 narrow down the number of pathways.

634

635 Network analyses

To further study the biological relevance of the findings from the differential methylation 636 637 analyses, the DMCs identified in the different comparisons described above were annotated to their corresponding gene symbols (DMGs) with the Illumina 850K platform annotation 638 639 reference. A total of 93 deprecated unique gene terms from the platform reference were corrected to the most updated nomenclature using the org.Hs.eg.db R package (version 640 641 3.10.0). Thereafter, the DMGs were used as seeds to construct the inputs for the disease module identification pipeline with MODifieR⁴⁰ R package (version 0.1.3, available at 642 https://gitlab.com/Gustafsson-lab/MODifieR). Four different module defining algorithms from 643 644 the package were implemented (Clique SuM, DIAMOnD, MCODE and Module Discoverer). and default parameters for the methods were used in each case. High confidence human 645 protein-protein interactions (PPI) were retrieved from the STRING database (version 11.0, 646 confidence score > 0.7). The four MODifieR methods were run for each comparison, resulting 647 in a set of gene lists corresponding to the identified modules. Non-biased consensus modules 648 were created for each comparison, by extracting genes found by all four module inference 649 methods. Network visualisation was conducted in Cytoscape (version 3.7.2). Pathway 650

enrichment analyses were performed on the module specific genes as described above to 651 652 elucidate the role of the different intervention combinations on the CD4+ T cells. Furthermore, to unravel subclusters within the modules, visual inspection of the networks along with pathway 653 654 enrichment analyses in the clusterProfiler R package (version 3.14.3, KEGG database) were performed. Clusters with three or more nodes were included in these analyses. Pathway 655 enrichment analyses were also performed for unique and shared genes within the networks. 656 657 To illustrate overlaps between shared and unique genes in the comparisons, Venn diagrams 658 were constructed using the VennDiagram R package (version 1.6.20). Furthermore, to 659 illustrate how the common genes may differ in methylation status between the comparisons. 660 river plots were constructed using the riverplot R package (version 0.6).

661

662 Comparisons of differential methylation and network results to publicly available allergy 663 data set

As we were interested in the relevance of our findings to allergic disease, but do not yet have 664 any data available on this from the children of the PROOM-3 study, we compared the findings 665 of our study with publicly available data on allergic disease. The chosen data set was 666 downloaded Expression Omnibus 667 from Gene (https://www.ncbi.nlm.nih.gov/geo/guery/acc.cgi?acc=GSE50222) and consisted of Illumina 668 450K data from CD4+ T cells from 8 adult patients vs. 8 controls with seasonal allergic rhinitis 669 with samples from both within and out of season (in total 32 samples).⁶¹ The data were pre-670 671 processed by removing probes located on the sex chromosomes, and filtering was performed 672 by removing probes having more than 20% NAs and imputing remaining NAs within retained probes using the KNN method (ChAMP, version 2.12.1). Thereafter, the data were normalised 673 using the BMIQ method and SVD analyses followed (Figure S12) as described earlier, showing 674 675 that no correction was needed. Subsequent differential DNA methylation analyses were performed using the limma package (version 3.42.2), and sex as well as season of sample 676 taking (within or outside of pollen season) were added as co-variates in the linear models. 677

Upon this, a total of 13102 DMCs were found for the data set, which were then compared to DMCs from our differential DNA methylation analyses and DMCs extracted from the genes identified in the respective network modules. Enrichment of any DMCs in these comparisons was performed using the enrichment function from the R package bc3net (version 1.0.4), based on a one-sided Fisher's exact test. As the data set originated from 450K data, the intersection of all 450K probes and all MethylationEPIC 850K probes excluding the sex chromosomes was used as background for the analysis, and only DMCs that were present in the background were included. Corresponding pathway enrichment analyses for genes overlapping between any of the differentially methylated DMCs or consensus module originating DMCs with the allergy data set were performed as described above.

701 ABBREVIATIONS

- 702 BMIQ beta mixture quantile
- 703 CBMC cord blood mononuclear cell
- 704 CFU colony forming unit
- 705 CpG Cytosine-phosphate-Guanine
- 706 DMC differentially methylated CpG
- 707 DMG differentially methylated gene
- 708 FDR false discovery rate
- 709 GW gestational week
- 710 L. reuteri Lactobacillus reuteri
- 711 LP single-treated *L.reuteri* + placebo group
- 712 $L\omega$ double-treated *L.reuteri* + ω -3 group
- 713 MDS multidimensional scaling
- 714 MMD mean methylation difference
- 715 PBMC peripheral blood mononuclear cell
- 716 PP double placebo group
- 717 PROOM-3 PRObiotics and OMega-3 study
- 718 $P\omega$ single-treated ω -3 + placebo group
- 719 SVD singular value decomposition
- 720 ω -3 omega-3 fatty acids
- 721

722 REFERENCES

- 723 1. Blaser MJ. The theory of disappearing microbiota and the epidemics of chronic diseases. Nature 724 Reviews Immunology. 2017;17:461-463.
- 725 2. Lambrecht BN, Hammad H. The immunology of the allergy epidemic and the hygiene 726 hypothesis. Nature immunology. 2017;18:1076-1083.
- 727 3. Simon KA, Hollander GA, McMichael A. Evolution of the immune system in humans from infancy 728 to old age. Proceedings Biological sciences / The Royal Society. 2015;282:20143085.
- 729 4. Gollwitzer ES, Marsland BJ. Impact of Early-Life Exposures on Immune Maturation and 730 Susceptibility to Disease. Trends in immunology. 2015;36:684-696.
- 731 5. Jenmalm MC. The mother-offspring dyad: microbial transmission, immune interactions and 732 allergy development. Journal of internal medicine. 2017;282:484-495.
- 733 6. Macpherson AJ, de Agüero MG, Ganal-Vonarburg SC. How nutrition and the maternal 734 microbiota shape the neonatal immune system. Nature reviews Immunology. 2017;17:508-517.
- 735 7. Julia V, Macia L, Dombrowicz D. The impact of diet on asthma and allergic diseases. Nature 736 Reviews Immunology. 2015;15:308-322.
- 737 8. Dzidic M, Boix-Amorós A, Selma-Royo M, Mira A, Collado M. Gut Microbiota and Mucosal Immunity in the Neonate. Medical sciences (Basel, Switzerland). 2018;6:56. 738
- 739 9. Renz H, Skevaki C. Early life microbial exposures and allergy risks: opportunities for prevention. Nature Reviews Immunology. 2020:1-15. 740
- 741 10. Miles EA, Calder PC. Can Early Omega-3 Fatty Acid Exposure Reduce Risk of Childhood 742 Allergic Disease? Nutrients. 2017;9:784.
- 743 11. Blasbalg TL, Hibbeln JR, Ramsden CE, Majchrzak SF, Rawlings RR. Changes in consumption 744 of omega-3 and omega-6 fatty acids in the United States during the 20th century. The American 745 Journal of Clinical Nutrition. 2011;93:950-962.
- 746 Warstedt K. Duchén K. Increased linoleic acid/a-linolenic acid ratio in Swedish cord blood 12. 747 samples collected between 1985 and 2005. European journal of nutrition. 2012;52:659-665.
- 748 13. Miyata J, Arita M. Role of omega-3 fatty acids and their metabolites in asthma and allergic 749 diseases. Allergology international : official journal of the Japanese Society of Allergology. 750 2015;64:27-34.
- 751 Krauss-Etschmann S, Hartl D, Rzehak P, et al. Decreased cord blood IL-4, IL-13, and CCR4 14. 752 and increased TGF- β levels after fish oil supplementation of pregnant women. Journal of Allergy 753 and Clinical Immunology. 2008;121:464-470000000.
- Bisgaard H, Stokholm J, Chawes BL, et al. Fish Oil-Derived Fatty Acids in Pregnancy and 754 15. 755 Wheeze and Asthma in Offspring. The New England journal of medicine. 2016;375:2530-2539.
- 756 16. Furuhjelm C, Warstedt K, Larsson J, et al. Fish oil supplementation in pregnancy and lactation 757 may decrease the risk of infant allergy. Acta Paediatrica. 2009;98:1461-1467.
- 758 Furuhjelm C, Warstedt K, Fagerås M, et al. Allergic disease in infants up to 2 years of age in 17. 759 relation to plasma omega-3 fatty acids and maternal fish oil supplementation in pregnancy and 760 lactation. Pediatric Allergy and Immunology. 2011;22:505-514.
- 761 Stokholm J, Blaser MJ, Thorsen J, et al. Maturation of the gut microbiome and risk of asthma in 18. 762 childhood. Nature Communications. 2018;9:141.
- 763 19. Bisgaard H, Li N, Bonnelykke K, et al. Reduced diversity of the intestinal microbiota during 764 infancy is associated with increased risk of allergic disease at school age. Journal of Allergy 765 and Clinical Immunology. 2011;128:646-65200000.
- Sjögren YM, Jenmalm MC, Böttcher MF, Björkstén B, Sverremark-Ekström E. Altered early 766 20. 767 infant gut microbiota in children developing allergy up to 5 years of age. Clinical and 768 experimental allergy : journal of the British Society for Allergy and Clinical Immunology. 769 2009;39:518-526.
- 770 21. Chiu C-Y, Chan Y-L, Tsai M-H, Wang C-J, Chiang M-H, Chiu C-C. Gut microbial dysbiosis is 771 associated with allergen-specific IgE responses in young children with airway allergies. The 772 World Allergy Organization journal. 2019;12:100021.
- 773 22. Ling Z, Li Z, Liu X, et al. Altered Fecal Microbiota Composition Associated with Food Allergy in 774 Infants. Applied and Environmental Microbiology. 2014;80:2546-2554.
- 775 Abrahamsson TR, Jakobsson HE, Andersson AF, Björkstén B, Engstrand L, Jenmalm MC. Low 23. 776 diversity of the gut microbiota in infants with atopic eczema. The Journal of allergy and clinical 777 immunology. 2012;129:434.
- 778 24. Cuello-Garcia CA, Brozek JL, Fiocchi A, et al. Probiotics for the prevention of allergy: A 779 systematic review and meta-analysis of randomized controlled trials. J Allergy Clin 780 Immunol.136.

781 782	25.	Wells JM. Immunomodulatory mechanisms of lactobacilli. <i>Microbial cell factories</i> . 2011;10 Suppl 1.
783	26.	Abrahamsson TR, Sandberg Abelius M, Forsberg A, Björkstén B, Jenmalm MC. A Th1/Th2-
784	20.	associated chemokine imbalance during infancy in children developing eczema, wheeze and
785		sensitization. Clinical and experimental allergy : journal of the British Society for Allergy and
786		Clinical Immunology. 2011;41:1729-1739.
787	27.	
	27.	Alhamwe B, Alhamdan F, Ruhl A, Potaczek DP, Renz H. The role of epigenetics in allergy and
788	00	asthma development. Current Opinion in Allergy and Clinical Immunology. 2020;20:48-55.
789	28.	Schmidl C, Delacher M, Huehn J, Feuerer M. Epigenetic mechanisms regulating T-cell
790	~~	responses. The Journal of allergy and clinical immunology. 2018;142:728-743.
791	29.	Zhang H, Kaushal A, Merid S, et al. DNA methylation and allergic sensitizations, a genome-
792		scale longitudinal study during adolescence. <i>Allergy.</i> 2019;74:1166-1175.
793	30.	Peng C, Meel ER, Cardenas A, et al. Epigenome-wide association study reveals methylation
794		pathways associated with childhood allergic sensitization. <i>Epigenetics</i> . 2019.
795	31.	DeVries A, Wlasiuk G, Miller SJ, et al. Epigenome-wide analysis links SMAD3 methylation at
796		birth to asthma in children of asthmatic mothers. J Allergy Clin Immunol.
797	32.	Lund RJ, Osmala M, Malonzo M, et al. Atopic asthma after rhinovirus-induced wheezing is
798		associated with DNA methylation change in the SMAD3 gene promoter. Allergy. 2018;73:1735-
799		1740.
800	33.	Martino D, Dang T, Sexton-Oates A, et al. Blood DNA methylation biomarkers predict clinical
801		reactivity in food-sensitized infants. J Allergy Clin Immunol.135.
802	34.	Martino D, Neeland M, Dang T, et al. Epigenetic dysregulation of naive CD4+ T-cell activation
803		genes in childhood food allergy. Nature Communications. 2018;9:3308.
804	35.	Harb H, Irvine J, Amarasekera M, et al. The role of PKCζ in cord blood T-cell maturation towards
805		Th1 cytokine profile and its epigenetic regulation by fish oil. <i>Bioscience Reports</i> . 2017;37.
806	36.	Amarasekera M, Noakes P, Strickland D, Saffery R, Martino DJ, Prescott SL. Epigenome-wide
807	00.	analysis of neonatal CD4(+) T-cell DNA methylation sites potentially affected by maternal fish
808		oil supplementation. <i>Epigenetics</i> .9.
809	37.	van Dijk SJ, Zhou J, Peters TJ, et al. Effect of prenatal DHA supplementation on the infant
810	07.	epigenome: results from a randomized controlled trial. <i>Clinical Epigenetics</i> . 2016;8:114.
811	38.	Vähämiko S, Laiho A, Lund R, Isolauri E, Salminen S, Laitinen K. The impact of probiotic
812	50.	supplementation during pregnancy on DNA methylation of obesity-related genes in mothers and
813		their children. European Journal of Nutrition. 2018:1-11.
813	39.	Forsberg A, Huoman J, Söderholm S, <i>et al.</i> Pre- and postnatal Lactobacillus reuteri treatment
815	59.	alters DNA methylation of infant T helper cells. <i>Pediatric Allergy and Immunology</i> . 2020.
	40	
816	40.	de Weerd HA, Badam TVS, Martínez-Enguita D, et al. MODifieR: an ensemble R package for
817		inference of disease modules from transcriptomics networks. <i>Bioinformatics (Oxford, England)</i> .
818	4.4	2020;36:3918-3919. D'Anvilla D. Correlli L. Denne, F. Desseries, C. Bellinni D. Cut Missekiste es lumentant Madiatas.
819	41.	D'Aquila P, Carelli L, Rango F, Passarino G, Bellizzi D. Gut Microbiota as Important Mediator
820		Between Diet and DNA Methylation and Histone Modifications in the Host. Nutrients.
821	4.0	2020;12:597.
822	42.	Ceccarelli V, Ronchetti S, Marchetti M, et al. Molecular mechanisms underlying
823		eicosapentaenoic acid inhibition of HDAC1 and DNMT expression and activity in carcinoma
824		cells. Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms. 2020;1863:194481.
825	43.	González-Becerra K, Ramos-Lopez O, Barrón-Cabrera E, et al. Fatty acids, epigenetic
826		mechanisms and chronic diseases: a systematic review. Lipids in Health and Disease.
827		2019;18:178.
828	44.	Salmond RJ, Filby A, Qureshi I, Caserta S, Zamoyska R. T-cell receptor proximal signaling via
829		the Src-family kinases, Lck and Fyn, influences T-cell activation, differentiation, and tolerance.
830		Immunological Reviews. 2009;228:9-22.
831	45.	Kaur S, Bansal Y, Kumar R, Bansal G. A panoramic review of IL-6: Structure, pathophysiological
832		roles and inhibitors. Bioorganic & Medicinal Chemistry. 2020;28:115327.
833	46.	Zhou X, Han X, Lyu S-C, et al. Targeted DNA methylation profiling reveals epigenetic signatures
834		in peanut allergy. JCI Insight. 2021.
835	47.	Baccarelli A, Rusconi F, Bollati V, et al. Nasal cell DNA methylation, inflammation, lung function
836		and wheezing in children with asthma. Epigenomics. 2012;4:91-100.
837	48.	Bruyns E, Marie-Cardine A, Kirchgessner H, et al. T Cell Receptor (TCR) Interacting Molecule
838		(TRIM), A Novel Disulfide-linked Dimer Associated with the TCR-CD3-ζ Complex, Recruits
839		Intracellular Signaling Proteins to the Plasma Membrane. The Journal of Experimental
840		Medicine. 1998;188:561-575.

medRxiv preprint doi: https://doi.org/10.1101/2021.03.25.21254287; this version posted March 26, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

perpetuity. It is made available under a CC-BY 4.0 International license .

- 841 49. Kirchgessner H, Dietrich J, Scherer J, et al. The Transmembrane Adaptor Protein Trim 842 Regulates T Cell Receptor (Tcr) Expression and Tcr-Mediated Signaling via an Association with 843 the Tcr ζ Chain. The Journal of Experimental Medicine. 2001;193:1269-1284. 844 Mehta AK, Gracias DT, Croft M. TNF activity and T cells. Cytokine. 2018;101:14-18. 50. Yamada A, Arakaki R, Saito M, Kudo Y, Ishimaru N. Dual Role of Fas/FasL-Mediated Signal in 845 51. 846 Peripheral Immune Tolerance. Frontiers in Immunology. 2017;8:403. 847 52. Abrahamsson TR, Jakobsson T, Böttcher MF, et al. Probiotics in prevention of IgE-associated 848 eczema: a double-blind, randomized, placebo-controlled trial. J Allergy Clin Immunol. 2007;119. 849 53. Solomon O, MacIsaac J, Quach H, et al. Comparison of DNA methylation measured by Illumina 850 450K and EPIC BeadChips in blood of newborns and 14-year-old children. Epigenetics. 2018:1-851 10 852 54. Tian Y, Morris TJ, Webster AP, et al. ChAMP: updated methylation analysis pipeline for Illumina BeadChips. Bioinformatics (Oxford, England). 2017;33:3982-3984. 853 854 Teschendorff AE, Marabita F, Lechner M, et al. A beta-mixture quantile normalization method 55. for correcting probe design bias in Illumina Infinium 450 k DNA methylation data. Bioinformatics 855 856 (Oxford, England). 2013;29:189-196. Morin AM, Gatev E, McEwen LM, et al. Maternal blood contamination of collected cord blood 857 56. 858 can be identified using DNA methylation at three CpGs. Clinical Epigenetics. 2017;9:75. 859 57. Houseman EA, Accomando WP, Koestler DC, et al. DNA methylation arrays as surrogate 860 measures of cell mixture distribution. BMC bioinformatics. 2012;13:86. 861 58. Johnson WE, Li C, Rabinovic A. Adjusting batch effects in microarray expression data using 862 empirical Bayes methods. Biostatistics (Oxford, England). 2007;8:118-127. 863 59. Leek JT, Johnson EW, Parker HS, Jaffe AE, Storey JD. The sva package for removing batch effects and other unwanted variation in high-throughput experiments. Bioinformatics. 864 865 2012;28:882-883. 866 van Iterson M, van Zwet EW, Consortium B, Heijmans BT. Controlling bias and inflation in 60. 867 epigenome- and transcriptome-wide association studies using the empirical null distribution. 868 Genome Biology. 2017;18:19. 869 61. Nestor CE, Barrenas F, Wang H, et al. DNA methylation changes separate allergic patients from healthy controls and may reflect altered CD4+ T-cell population structure. PLoS Genet.10. 870 871 872 873 874 875 876 877
 - 878
 - 879
 - 880
 - 000
 - 881

882 **DECLARATIONS**

- 883 Ethics approval and consent to participate
- 884 Parents or legal guardians provided informed consent on behalf of the children prior to
- inclusion in the study. Ethical permission for this study has been granted by the Regional Ethics
- 886 Committee for Human Research in Linköping (Dnr 2011/45-31).
- 887 Consent for publication
- 888 Not applicable
- 889 Availability of data and materials
- 890 The datasets used and/or analysed during the current study are available from the 891 corresponding author on reasonable request.
- 892 Competing interests
- 893 The authors report no conflicts of interest.
- 894 Funding

This study was supported by grants from the Swedish Research Council (2016-01698 and 2019-00989); the Swedish Heart and Lung Foundation (20140321 and 20170365); the Cancer and Allergy Foundation and the Medical Research Council of Southeast Sweden (FORSS-666771 and FORSS-758981).

899 Author's contributions

M.C.J and K.D. designed the study. K.D. and L.N. were responsible for the clinical evaluation of the children. J.H. has taken part in the sample collection and performed the experimental work presented in this paper. J.E. provided expertise on flow cytometry analyses, and M.G. on the performance of the statistical and bioinformatic analyses. D.M.E., E.O. and J.H. performed the statistical and bioinformatic analyses. J.H. presented the findings. All authors interpreted

and discussed the results. J.H. drafted the manuscript. All authors contributed to and approvedthe final draft for publication.

907 Acknowledgments

908 Firstly, we would like to thank the children and mothers included in this study for their participation, and the personnel at the Allergy Center, Linköping for professionally taking care 909 of the families throughout the study period, as well as handling samples in preparation for 910 911 laboratory work. Our warmest thanks go to our skilled laboratory technicians Camilla Janefjord 912 and Anne-Marie Fornander, for their unfailing collection of samples from the PROOM-3 study. 913 We would also like to thank Simon Söderholm for valuable input in the initial analyses of the DNA methylation data. Lastly, we would like to acknowledge BioGaia® AB and Orkla Health 914 915 for sponsoring the dietary supplements used in this study, as well as the SNP&SEQ-technology platform at SciLifeLab Uppsala University for yet another constructive collaboration. 916

- 917 Author's information
- 918 Not applicable

919